Modus down 50% after serious adverse event pauses sevuparin kidney disease trial

15 October 2026

Shares in Swedish biotech Modus Therapeutics (STO: MODTX) fell by half in Stockholm trading on Thursday after the company paused enrollment in part two of its Phase IIa study of sevuparin in chronic kidney disease (CKD) with anemia. Majority owner KD Ventures, which holds 51%, fell about 5%.

Modus announced the pause on Wednesday evening as a voluntary, precautionary measure. It followed a serious adverse event in a patient treated with sevuparin that was reported to regulators as a suspected unexpected serious adverse reaction (SUSAR), and a review with the study’s safety committee. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical